Colorectal Neoplasms

• EMA approval · 2026-07-22
  EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament

  The EMA authorises Braftovi (encorafenib) for melanoma and colorectal neoplasms.

• EMA approval · 2026-07-15
  EMA Authorised: Erbitux (cetuximab) — Merck Europe B.V.

  Erbitux (cetuximab) has been authorised by EMA for therapeutic areas including head and neck neoplasms and colorectal neoplasms.

• EMA approval · 2026-07-08
  EMA Authorised: Fruzaqla (fruquintinib) — Takeda Pharmaceuticals International AG Ireland

  Authorised medicinal product Fruzaqla (fruquintinib) for colorectal neoplasms in the EU.

• EMA approval · 2026-07-07
  EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited

  EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.

• EMA approval · 2026-07-01
  EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament

  EMA authorises Braftovi (Encorafenib) for melanoma and colorectal neoplasms.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2026-06-24
  EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG

  Authorised approval for Yervoy (ipilimumab) with multiple indications including melanoma and various carcinomas and mesothelioma; decision d…

• EMA approval · 2025-07-11
  EMA Authorised: Capecitabine Teva (capecitabine) — Teva Pharma B.V.

  EMA authorised Capecitabine Teva (capecitabine), a generic capecitabine product by Teva Pharma B.V., for multiple cancer indications, includ…

• EMA approval · 2025-06-17
  EMA Authorised: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) — Cosmo Technologies Ltd

  Lumeblue, containing methylthioninium chloride, has been authorised by the EMA for use in colorectal neoplasms and during colonoscopy.

• EMA approval · 2025-05-07
  EMA Authorised: Vectibix (panitumumab) — Amgen Europe B.V.

  EMA authorised Vectibix (panitumumab) for colorectal neoplasms, with Amgen Europe B.V. as the marketing authorization holder; decision date …

• EMA approval · 2024-11-27
  EMA Authorised: Fruzaqla (fruquintinib) — Takeda Pharmaceuticals International AG Ireland

  The European Medicines Agency authorised Fruzaqla (fruquintinib) for colorectal neoplasms, with Takeda Pharmaceuticals International AG Irel…

• EMA approval · 2024-04-05
  EMA Authorised: Lonsurf (trifluridine;tipiracil hydrochloride) — Les Laboratoires Servier

  EMA authorised Lonsurf (trifluridine and tipiracil) for colorectal neoplasms; decision dated 26/07/2023.